IDRA Insider Trading Activity and SEC Form 4 Filings
IDRA insider trading summary
No open-market insider purchases or sales of Idera Pharmaceuticals, Inc. (IDRA) have been reported on SEC Form 4 in the past 12 months.
Latest IDRA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 17, 2021 | John J. Kirby | Chief Financial Officer | Buy | $6K (10,000 @ $0.61) |
| Jun 18, 2021 | Daniel B Soland | Chief Operating Officer | Buy | $60K (50,000 @ $1.19) |
| Jun 1, 2021 | Michael R Dougherty | Insider | Buy | $101K (85,000 @ $1.19) |
| Mar 25, 2021 | Elizabeth Ann Tarka | Chief Medical Officer | Sell | $7K (5,018 @ $1.35) |
| Mar 25, 2021 | John J. Kirby | Chief Financial Officer | Sell | $9K (6,250 @ $1.42) |
| Mar 25, 2021 | Bryant David Lim | SVP and General Counsel | Sell | $10K (7,630 @ $1.36) |
| Mar 18, 2021 | Pillar Partners Foundation, L.P. | 10% Owner | Sell | $2.5M (1,376,039 @ $1.80) |
| Mar 18, 2021 | Pillar Invest Corp | 10% Owner | Sell | $2.5M (1,376,039 @ $1.80) |
| Mar 18, 2021 | Abude Umari | 10% Owner | Sell | $2.5M (1,376,039 @ $1.80) |
| Mar 18, 2021 | Pillar Invest Corp | 10% Owner | Sell | $582K (323,726 @ $1.80) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.